Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

Rheumatoid Arthritis Clinical Trial

— RA  

Official title:

Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02053727
• Other study ID #: IM101329
• Secondary ID: 13-001279
• Status: Withdrawn
• Phase: N/A
• Start date: July 2014
• Est. completion date: June 12, 2018

Study information

• Verified date: November 2020
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate whether the combination of abatacept along with entecavir (the study drugs) is safe and effective in treating symptoms related to rheumatoid arthritis (RA).

Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form, is approved by the FDA for the treatment of RA. In this research, abatacept will be given by injection. A subcutaneous injection is an injection given under the skin.

Entecavir, to be taken by mouth, is approved by the FDA for the treatment of hepatitis B.

The study is divided into the following time periods:

Screening Phase: Up to 4 weeks Randomized Double-blind Phase: 24 weeks Open-label Extension Phase: 24 weeksFollow-up Phase: a phone call after Week 48

Each phase contains one or more study visits.

Description:

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder affecting 1% of the world's population. If not adequately controlled, it may lead to disability in up to 30% of patients within the first three years of disease onset [1] and can be associated with premature death. Recent research has suggested that the first event in the pathogenesis of RA is an antigen dependent activation of T-cells in an immunogenetically susceptible host. T-cells require two signals for activation, one involving the trimolecular complex (class II Major Histocompatibility Complex (MHC), antigen, T-cell receptor), and the other being co-stimulation of the CD28 (Cluster of Differentiation 28) molecule on T-cells by the B7 molecules (CD80 and CD86) on antigen presenting cells.

Hepatitis B virus (HBV) can cause chronic disease in 5% of immunocompetent adults and has a prevalence of over 350 million worldwide. It is a leading cause of chronic hepatitis, cirrhosis and hepatocellular cancer and accounts for one million deaths annually. In patients with chronic hepatitis B and RA, treatment options are limited. Traditional disease modifying anti-rheumatic drugs (DMARDs) are associated with hepatotoxicity and are contraindicated in chronic hepatitis. A recent retrospective analysis suggests that successful use of anti-tumor necrosis factor alpha (anti-TNF) agents may be possible in these patients but the authors do warn that these patients should be closely monitored and that fatal reactivation of hepatitis B is possible. Treatment with rituximab, a chimeric monoclonal antibody against B-cell protein CD20, is another option; however, the use of this medication in RA patients with chronic hepatitis B may also cause reactivation.

When RA patients with chronic hepatitis B were started on a Tumor Necrosis Factor (TNF) inhibitor or methotrexate (MTX), 2 of 5 HBsAg+ patients reactivated their hepatitis B, indicating a possible high rate of activation in these patients when not on hepatitis B treatment. Reactivation in this and another study occurred after 9-19 months of antirheumatic therapy. In RA patients with chronic Hepatitis B, entecavir appears to be effective at preventing reactivation.

There are no studies on the safety of abatacept in patients with RA and HBV. Adequate T-cell function is important to help cure or contain HBV infection. Our site has conducted a retrospective study that shows preliminary safety of abatacept in patients with RA and chronic Hepatitis B on antiviral therapy. The purpose of this study is to assess the safety and efficacy of abatacept in RA patients with chronic Hepatitis B in a pilot study in a randomized, controlled fashion.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 12, 2018
• Est. primary completion date: June 12, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosis of RA.

2. Baseline CDAI >10 with TJC (Tender Joint Count) > 4 and SJC (Swollen Joint Count) > 2.

3. Chronic Hepatitis B as defined by a history of patients with a HBsAg positive for at least 6 months with undetectable HBV DNA; or a history of patients with negative HBsAg and positive HBcAb or HBsAb, with undetectable HBV DNA.

4. No evidence of hepatocellular carcinoma (HCC) based upon alpha-fetoprotein (AFP) =20 ng/mL at screening,) negative liver imaging as shown by ultrasound, computerized tomography or magnetic resonance imaging within 24 weeks of screening. Participants with AFP >20 ng/mL must be evaluated clinically with additional imaging and shown not to have HCC on CT or MRI before they can be enrolled.

5. Oral corticosteroids (= 10 mg/day of prednisone or equivalent) and NSAIDs (Non-Steroidal Anti-inflammatory Drugs) are permitted if the patient is on a stable dose regimen for = 2 weeks prior to and including at baseline.

6. Men and women, >= 18 years of age.

Exclusion Criteria:

1. Women who are pregnant or breastfeeding. Sexually active fertile men not using effective birth control if their partners are WOCBP (Women of Child Bearing Potential).

2. Target Disease Exceptions

a) Rheumatic autoimmune disease other than RA; fibromyalgia or keratoconjunctivitis/xerostomia are allowed, as long as these will not confound the CLINICAL EFFICACY OUTCOMES.

3. Medical History and Concurrent Diseases

1. Subjects who are impaired, incapacitated, or incapable of completing study-related assessments.

2. Subjects who underwent previous MCP (metacarpophalangeal) arthroplasty, have such a procedure scheduled, or anticipate the need for such a procedure during the study.

3. Major surgery (including joint surgery) within 8 weeks prior to screening

4. Subjects with active vasculitis of a major organ system, with the exception of rheumatoid nodules or minor rheumatoid vasculitis lesions of the skin

5. Subjects with current uncontrolled symptoms of severe, progressive, or uncontrolled renal, hepatic hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, including Cirrhosis with Child-Pugh Class >=2 or COPD (chronic obstructive pulmonary disease) with FEV1 (forced expiratory volume in 1 second) /FVC (forced vital capacity) < 0.6

6. Female subjects who have had a recent breast cancer screening that is suspicious for malignancy and where the diagnosis is not excluded.

h) Subjects who currently abuse drugs or alcohol. i) Subjects with evidence of active or latent bacterial or viral infections at the time of potential enrollment, including HIV.

j) Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed.

k) Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication.

l) Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection.

m) Subjects at risk for tuberculosis (TB) or not treated for latent TB is tested positive.

n) Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.

o) Subjects who have abnormal laboratory values

4. Prohibited Treatments and/or Therapies

1. Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose.

2. Any concomitant biologic DMARD, such as anakinra.

3. Previous treatment with cell-depleting therapies, including investigational agents, including but not limited to CAMPATH, anti-CD4 (cluster of differentiation 4), anti-CD5, anti-CD3, and anti-CD19.

4. Anti-CD20 treatment within the last 6 months (OK to include if they were dosed > 6 months ago).

5. Treatment with methotrexate, hydroxychloroquine, cyclosporine A, azathioprine, mycophenolate mofetil, within <= 4 weeks prior to baseline.

6. Treatment with etanercept within 2 weeks, infliximab/certolizumab/golimumab/adalimumab with <=8 weeks, anakinra within <=1 week prior to baseline.

7. Previous abatacept use.

8. Treatment with sulfasalazine within < 4 weeks prior to baseline

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Chronic Hepatitis B
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Rheumatoid Arthritis

Intervention

Drug:
• Abatacept
Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
• Placebo

Locations

Country	Name	City	State
United States	Division of Rheumatology, UCLA David Geffen School of Medicine	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Serious Adverse Events	Adverse events will be assessed at timepoints specified in the protocol.	Every 4 weeks from Week 4 to Week 48
Primary	Number of Subjects with Hepatitis B Reactivation	Blood test for Hepatitis B Virus (HBV) DNA will be used.	Every 4 Weeks from Week 4 to Week 48
Secondary	DAS28-ESR-4 Unit		Screening, Weeks 4, 8, 12, 24, 36, and 48
Secondary	CDAI Unit		Screening, Weeks 4,8,12,24,36,48
Secondary	TJC Count		Screening, Weeks 4,8,12,24,36,48
Secondary	SJC Count		Screening, Weeks 4,8,12,24,36,48
Secondary	Patient Global (Visual Analogue Scale)		Screening, Weeks 4,8,12,24,36,48
Secondary	MD Global (Visual Analogue Scale)		Screening, Weeks 4,8,12,24,36,48
Secondary	Pain (measured on a 5 point Likert scale)		Screening, Weeks 4,8,12,24,36,48
Secondary	Global Assessment of Disease Activity (as measured on a 5 point Likert scale)		Screening, Weeks 4,8,12,24,36,48
Secondary	HAQ-DI Units		Screening, Weeks 4,8,12,24,36,48
Secondary	Fatigue (as assessed by FACIT-Fatigue Unit)		Screening, Weeks 4,8,12,24,36,48
Secondary	Sleep as assessed by Medical Outcomes Study Sleep Instrument Unit		Screening, Weeks 4,8,12,24,36,48
Secondary	ACR 20/50/70 Percentage		Screening, Weeks 4,8,12,24,36,48